Photodynamic therapy (PDT) is a clinically appropriate therapeutic procedure with a minimum invasion that can apply a selective cytotoxic effect toward intended cells. Generally, PDT involves the administration of light and a photosensitive drug (photosensitizer). In the presence of oxygen molecules, the excited photosensitizer can produce reactive oxygen species (ROS) to kill the cancerous cells. In PDT, drug or light can administrate in high doses at short time (acute PDT) or in low doses in a period of time (metronomic PDT). In addition, to solve the problem of light access to the tissues, new modality that named Self Light PDT (SLPDT), was introduced recently. According to the studies, LaF₃:Tb conjugated with meso-tetra(4-carboxyphenyl) porphine (MTCP) nanosystem can function as an efficient nanosystem in SLPDT due to the ability of energy transfer between the light-exited NPs and MTCP to emissions which can generate ROS. In this research besides synthesizing and characterizing LaF₃:Tb-MTCP nanosystems, we also studied energy transfer feasibility under UV radiation between NP and PS. Afterward, we tried to design several in vitro test using breast cancer cell lines, T47D and mcf-7, to understanding LaF3:Tb conjugated MTCP potentials for SLPDT or mPDT.

光动力疗法（PDT）是一种临床上适当的治疗方法，具有最小的侵袭能力，可以对目标细胞施加选择性的细胞毒作用。通常，PDT涉及光和光敏药物（光敏剂）的施用。在存在氧分子的情况下，激发的光敏剂可产生活性氧（ROS）杀死癌细胞。在PDT中，药物或光可以在短时间内以高剂量（急性PDT）或在一段时间内以低剂量（Metronomic PDT）给药。另外，为了解决光进入组织的问题，最近引入了一种称为自发光PDT（SLPDT）的新形式。根据研究，LaF ₃：Tb与内消旋四（4-羧基苯基）卟啉（MTCP）纳米系统共轭，可在SLPDT中用作高效的纳米系统，这是因为光发射的NP和MTCP之间的能量转移能力可产生ROS。在这项研究中，除了合成和表征LaF ₃：Tb-MTCP纳米系统外，我们还研究了NP和PS之间在紫外线辐射下的能量转移可行性。之后，我们试图设计使用乳腺癌细胞系T47D和mcf-7进行的几种体外测试，以了解LaF3：Tb结合的MTCP对SLPDT或mPDT的潜力。